Strata Critical Medical (SRTA) Financials
Ticker history: BLDE became SRTA (Strata Critical Medical, Inc.) on . Earlier news and filings retain their original names and dates. View BLDE history.
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 4, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 3, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the SRTA SEC filings page.
Strata Critical Medical, Inc. (SRTA) reported $280.8M in revenue over the twelve months to Sep 30, 2026, up 68.4% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2025 produced accounting profit, but the operating engine still consumed cash and remained loss-making.
The 2025 net profit of$41.3M coexisted with operating cash flow of-$48.9M while operations remained loss-making, indicating the reported profit came from accounting items outside the core operating engine. The FCF margin fell6.9 percentage points to-29.7% even though capital expenditures were only4.9% of revenue, pointing to operating cash weakness rather than unusually heavy reinvestment.
The balance sheet is lightly leveraged: the current ratio was 6.4x and liabilities were
Gross margin reached
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Strata Critical Medical, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Strata Critical Medical, Inc. has an operating margin of -11.3%, meaning the company loses $11 on every $100 of revenue. This results in a profitability score of 26/100. This is up from -15.3% the prior year.
Strata Critical Medical, Inc.'s revenue surged 34.3% year-over-year to $197.1M, reflecting rapid business expansion. This strong growth earns a score of 14/100.
With a current ratio of 6.38, Strata Critical Medical, Inc. holds $6.38 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 95/100.
Strata Critical Medical, Inc.'s operations used $48.9M of cash, and capex of $9.6M added to the outflow, for a free cash flow shortfall of $58.5M. This results in a cash flow score of 8/100.
Strata Critical Medical, Inc. generates a 14.8% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 28/100. This is up from -12.3% the prior year.
Strata Critical Medical, Inc. scores 6.12, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $461.8M against total liabilities of $46.4M. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Strata Critical Medical, Inc. passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Strata Critical Medical, Inc. used $1.18 of operating cash (-$48.9M OCF vs $41.3M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
Key Financial Metrics
Earnings & Revenue
Strata Critical Medical, Inc. generated $74.1M in revenue in Q3 2026. This represents an increase of 50.3% from the same quarter a year earlier. Against the prior quarter it is up 2.2%.
Strata Critical Medical, Inc.'s EBITDA was $3.5M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is up 12.0%.
Strata Critical Medical, Inc. reported a net loss of $7.6M in Q3 2026. This represents a decrease of 113.3% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Strata Critical Medical, Inc. earned -$0.09 per diluted share (EPS) in Q3 2026. This represents a decrease of 112.9% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
Strata Critical Medical, Inc. generated $9.1M in free cash flow in Q3 2026, representing cash available after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is up 183.3%.
Strata Critical Medical, Inc. held $35.1M in cash as of Q3 2026; no long-term debt figure is on record for that period.
Not reported for Q3 2026.
Margins & Returns
Strata Critical Medical, Inc.'s gross margin was 22.7% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is up 1.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.7 percentage points.
Strata Critical Medical, Inc.'s operating margin was -5.2% in Q3 2026, reflecting core business profitability. This is up 6.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.3 percentage points.
Strata Critical Medical, Inc.'s net profit margin was -10.3% in Q3 2026, showing the share of revenue converted to profit. Against the prior quarter it is up 4.2 percentage points. No change is given against Q3 2025: its reported ratio is above 100.0% of revenue, so it does not read as a share of revenue.
Strata Critical Medical, Inc.'s quarterly ROE was -2.8% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 23.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.0 percentage points.
Capital Allocation
Strata Critical Medical, Inc. invested $400K in capex in Q3 2026, funding long-term assets and infrastructure. This represents a decrease of 86.2% from the same quarter a year earlier. Against the prior quarter it is down 83.9%.
Not reported for Q3 2026.
Not reported for Q3 2026.
SRTA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $74.1M+50.3% | $72.5M+60.7% | $67.4M+87.4% | $66.8M+83.5% | $49.3M+36.7% | $45.1M-33.6% | $35.9M-30.2% | $36.4M-23.4% |
| Cost of Revenue | $57.3M+48.2% | $57.3M+58.7% | $53.3M+84.3% | $53.3M+70.0% | $38.6M+35.3% | $36.1M-30.0% | $28.9M-30.2% | $31.4M-18.4% |
| Gross Profit | $16.8M+57.9% | $15.2M+68.9% | $14.1M+100.2% | $13.5M | $10.7M+41.9% | $9.0M-44.9% | $7.1M-30.4% | N/A |
| SG&A Expenses | $15.1M-4.9% | $14.0M+5.3% | $15.6M+26.6% | $18.5M | $15.9M+12.2% | $13.3M-51.7% | $12.3M-36.2% | N/A |
| Operating Income | -$3.8Mn/m | -$5.4Mn/m | -$3.0Mn/m | -$6.4Mn/m | -$5.6Mn/m | -$4.6Mn/m | -$5.7Mn/m | -$5.9Mn/m |
| EBITDA | $3.5Mn/m | $3.1Mn/m | $86Kn/m | -$3.4M | -$3.9Mn/m | -$2.9Mn/m | -$4.0Mn/m | N/A |
| Income Tax | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0-100.0% | $0n/m | -$105Kn/m |
| Net Income | -$7.6M-113.3% | -$10.5Mn/m | $2.2Mn/m | -$8.8Mn/m | $57.4Mn/m | -$3.7Mn/m | -$3.5Mn/m | -$9.8Mn/m |
| EPS (Basic) | -$0.09-112.9% | -$0.12n/m | $0.03n/m | -$0.12n/m | $0.70n/m | -$0.05n/m | -$0.04n/m | -$0.12n/m |
| EPS (Diluted) | -$0.09-112.9% | -$0.12n/m | $0.03n/m | -$0.12n/m | $0.70n/m | -$0.05n/m | -$0.04n/m | -$0.12n/m |
| Diluted Shares (Avg) | 88M+7.1% | 86M+6.0% | 90M+12.9% | N/A | 82M+5.7% | 81M+4.8% | 80M+5.4% | N/A |
Not reported in any period shown, so not listed: R&D Expenses, Interest Expense.
SRTA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $328.9M-1.8% | $332.7M+29.0% | $327.6M+30.8% | $325.5M+26.8% | $335.1M+18.4% | $257.9M-8.0% | $250.6M-11.4% | $256.7M-13.0% |
| Current Assets | $125.1M+2.2% | $121.0M-22.7% | $124.1M-18.5% | $126.2M-21.5% | $122.5M-28.7% | $156.5M-14.5% | $152.3M-21.5% | $160.7M-22.1% |
| Cash & Equivalents | $35.1M+54.4% | $16.3M-72.2% | $58.7M+68.6% | $31.0M+68.5% | $22.8M+13.6% | $58.8M+123.3% | $34.8M-5.2% | $18.4M-34.1% |
| Short-Term Investments | $6.5M-87.8% | $6.4M-88.2% | $66K-99.9% | $30.3M-72.2% | $53.2M-54.3% | $54.7M-52.7% | $85.2M-25.4% | $108.8M-21.3% |
| Accounts Receivable | $42.8M+13.9% | $43.4M+54.1% | $39.6M+79.0% | $40.0M+101.6% | $37.5M+53.3% | $28.2M+1.6% | $22.1M-6.0% | $19.8M-5.6% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Goodwill | $101.9M+20.5% | $106.9M+141.7% | $88.6M+110.7% | $88.2M+467.6% | $84.6M+97.0% | $44.3M+11.8% | $42.0M+5.7% | $15.5M+16.6% |
| Total Liabilities | $52.5M+0.8% | $53.4M+53.3% | $41.9M+35.9% | $46.4M+33.6% | $52.1M+5.3% | $34.8M-31.7% | $30.8M-33.3% | $34.7M-42.7% |
| Current Liabilities | $45.1M+61.9% | $45.8M+74.0% | $20.9M-4.3% | $19.8M-12.9% | $27.9M+2.5% | $26.3M-13.1% | $21.9M-5.9% | $22.7M-36.0% |
| Non-Current Liabilities | $7.4M-69.5% | $7.6M-10.7% | $20.9M+134.4% | $26.6M+121.5% | $24.2M+8.7% | $8.5M-58.8% | $8.9M-61.0% | $12.0M-52.2% |
| Total Equity | $276.4M-2.3% | $279.3M+25.2% | $285.7M+30.0% | $279.1M+25.7% | $283.0M+21.2% | $223.1M-2.7% | $219.7M-7.1% | $221.9M-5.3% |
| Retained Earnings | -$161.5Mn/m | -$153.9Mn/m | -$143.4Mn/m | -$145.6Mn/m | -$136.7Mn/m | -$194.1Mn/m | -$190.4Mn/m | -$186.9Mn/m |
Not reported in any period shown, so not listed: Inventory, Long-Term Debt.
SRTA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $9.5Mn/m | $5.7Mn/m | $3.9Mn/m | -$8.3Mn/m | -$37.3M-686.9% | -$3.1M-136.4% | -$246Kn/m | -$1.8Mn/m |
| Depreciation & Amortization | $7.3M+329.1% | $8.5M+379.4% | $3.1M+80.3% | $3.0M+96.6% | $1.7M+33.2% | $1.8M+13.9% | $1.7M+6.5% | $1.5M-15.3% |
| Stock-Based Compensation | N/A | N/A | $5.0M+19.4% | N/A | N/A | N/A | $4.2M-2.3% | N/A |
| Capital Expenditures | $400K-86.2% | $2.5M+11.4% | $5.2M+98.1% | $1.8M-59.6% | $2.9M-68.9% | $2.2M-86.2% | $2.6M+220.3% | $4.6M+18966.7% |
| Free Cash Flow | $9.1Mn/m | $3.2Mn/m | -$1.3Mn/m | -$10.2Mn/m | -$40.2Mn/m | -$5.3Mn/m | -$2.9Mn/m | -$6.3Mn/m |
| Investing Cash Flow | $13.5M+461.3% | -$43.9M-253.0% | $24.7M+21.2% | $18.3M+359.4% | $2.4Mn/m | $28.7Mn/m | $20.4M-16.9% | $4.0M+5201.3% |
| Financing Cash Flow | -$4.1Mn/m | -$4.2Mn/m | -$859Kn/m | -$1.7Mn/m | -$1.8Mn/m | -$1.1Mn/m | -$4.2M-7963.0% | -$3.9Mn/m |
| Share Buybacks | N/A | N/A | N/A | $0n/m | $0n/m | N/A | N/A | $0n/m |
Not reported in any period shown, so not listed: Dividends Paid.
SRTA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 22.7%+1.1pp | 21.0%+1.0pp | 20.9%+1.3pp | 20.1% | 21.6%+0.8pp | 20.0%-4.1pp | 19.6%-0.1pp | N/A |
| Operating Margin | -5.2%+6.2pp | -7.5%+2.8pp | -4.4%+11.4pp | -9.6%+6.6pp | -11.4%+8.3pp | -10.3%+7.6pp | -15.8%+3.4pp | -16.2%+58.8pp |
| Net Margin | -10.3% | -14.5%-6.2pp | 3.2%+12.9pp | -13.2%+13.7pp | 116.5% | -8.3%+8.4pp | -9.7%-1.5pp | -26.9%+44.6pp |
| Return on Equity | -2.8%-23.0pp | -3.8%-2.1pp | 0.8%+2.3pp | -3.2%+1.2pp | 20.3%+21.1pp | -1.7%+3.3pp | -1.6%+0.2pp | -4.4%+10.1pp |
| Return on Assets | -2.3%-19.5pp | -3.2%-1.7pp | 0.7%+2.0pp | -2.7%+1.1pp | 17.1%+17.8pp | -1.5%+2.6pp | -1.4%+0.1pp | -3.8%+7.7pp |
| Current Ratio | 2.77-1.6x | 2.64-3.3x | 5.93-1.0x | 6.38-0.7x | 4.39-1.9x | 5.95-0.1x | 6.96-1.4x | 7.07+1.3x |
| Liabilities-to-Equity | 0.190.0x | 0.190.0x | 0.150.0x | 0.170.0x | 0.180.0x | 0.16-0.1x | 0.14-0.1x | 0.16-0.1x |
| Asset Turnover | 0.23+0.1x | 0.220.0x | 0.21+0.1x | 0.21+0.1x | 0.150.0x | 0.17-0.1x | 0.140.0x | 0.140.0x |
| FCF Margin | 12.2%+93.8pp | 4.4%+16.2pp | -1.9%+6.0pp | -15.2%+2.2pp | -81.5%-73.3pp | -11.8%-0.4pp | -8.0%+23.8pp | -17.4%+2.3pp |
Not reported in any period shown, so not listed: Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Strata Critical Medical, Inc. SRTA | FY2025 | $197.1M | $41.3M | 21.0% | $461.8M | 42/100 |
| Community Health Systems, Inc. CYH | FY2025 | $12.5B | $509.0M | 4.1% | $335.6M | 40/100 |
| Auna S.A. AUNA | FY2025 | $1.3B | $29.0M | 2.2% | $342.9M | 57/100 |
| InnovAge Holding Corp. INNV | FY2026 | $989.7M | -$2.5M | -0.3% | $1.3B | 48/100 |
| Healthcare Services Group HCSG | FY2025 | $1.8B | $59.1M | 3.2% | $1.8B | 61/100 |
| The Pennant Group, Inc. PNTG | FY2025 | $947.7M | $29.6M | 3.1% | $1.5B | 48/100 |
Where Strata Critical Medical, Inc. Ranks
Frequently Asked Questions
Strata Critical Medical, Inc. (SRTA) reported $197.1M in total revenue for fiscal year 2025. This represents a 34.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Strata Critical Medical, Inc. (SRTA) revenue grew by 34.3% year-over-year, from $146.8M to $197.1M in fiscal year 2025.
No, Strata Critical Medical, Inc. (SRTA) reported a net loss of $24.8M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net income of $41.3M, with a net profit margin of 21.0%.
Strata Critical Medical, Inc. (SRTA) had EBITDA of -$14.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
Strata Critical Medical, Inc. (SRTA) had a gross margin of 20.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
Strata Critical Medical, Inc. (SRTA) had an operating margin of -11.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
Strata Critical Medical, Inc. (SRTA) had a net profit margin of 21.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Strata Critical Medical, Inc. (SRTA) has a return on equity of 14.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Strata Critical Medical, Inc. (SRTA) recorded an outflow of $58.5M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Strata Critical Medical, Inc. (SRTA) recorded an outflow of $48.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Strata Critical Medical, Inc. (SRTA) had $325.5M in total assets as of fiscal year 2025, including both current and long-term assets.
Strata Critical Medical, Inc. (SRTA) invested $9.6M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Strata Critical Medical, Inc. (SRTA) had a current ratio of 6.38 as of fiscal year 2025, which is generally considered healthy.
Strata Critical Medical, Inc. (SRTA) had a liabilities-to-equity ratio of 0.17 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
Strata Critical Medical, Inc. (SRTA) had a return on assets of 12.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Strata Critical Medical, Inc. (SRTA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $461.8M as of Nov 4, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Strata Critical Medical, Inc. (SRTA) trades at 1.6x sales, its market capitalization divided by $280.8M revenue, trailing 12 months to September 30, 2026. The market capitalization is $461.8M as of Nov 4, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2025, Strata Critical Medical, Inc. (SRTA) held $61.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $48.9M over that year. Dividing the one by the other, the reported balance equals about 15 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Strata Critical Medical, Inc. (SRTA) has an Altman Z-Score of 6.12, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
Strata Critical Medical, Inc. (SRTA) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
For every $1 of reported earnings, Strata Critical Medical, Inc. (SRTA) used $1.18 of operating cash (-$48.9M OCF vs $41.3M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Strata Critical Medical, Inc. (SRTA) scores 42 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.